Tetraphase Pharma (TTPH) Tops Q3 EPS by 70c

Tetraphase Pharma (NASDAQ: TTPH) reported Q3 EPS of ($6.00), $0.70 better than the analyst estimate of ($6.70). Revenue for the quarter came in at $3.34 million versus the consensus estimate of $3.52 million.

“XERAVA has now been on the market for just over a year, and during that time we have made significant progress, particularly in the third quarter, with 30% carton growth over last quarter, leading to a 23% increase in net XERAVA revenue compared with the previous quarter,” said Larry Edwards, President and Chief Executive Officer of Tetraphase. “We are squarely focused on continuing to increase formulary uptake and pull-through, as we believe XERAVA is a critically important new addition to the hospital antibiotic armamentarium, and that increased formulary uptake and pull through will result in increased sales. With our recent equity offering and payoff of debt, we are now in a stronger financial position to execute on these goals.”

For earnings history and earnings-related data on Tetraphase Pharma (TTPH) click here.

You May Also Be Interested In

• Equifax (EFX) shares tumble on weak Q1 revenue, guidance miss
• ABB shares jump as 2024 profitability outlook hike offsets Q1 revenue miss
• Intrepid Potash (IPI) Grants CEO Temporary Medical Leave of Abscence